MedKoo Cat#: 540301 | Name: Molsidomine
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Molsidomine is a NO donor and annexin A2 inhibitor. It inhibits PDGF-induced smooth muscle cell migration, suppresses carotid artery neointima formation, and prevents activated platelet adhesion.

Chemical Structure

Molsidomine
Molsidomine
CAS#25717-80-0

Theoretical Analysis

MedKoo Cat#: 540301

Name: Molsidomine

CAS#: 25717-80-0

Chemical Formula: C9H14N4O4

Exact Mass: 242.1015

Molecular Weight: 242.24

Elemental Analysis: C, 44.63; H, 5.83; N, 23.13; O, 26.42

Price and Availability

Size Price Availability Quantity
1g USD 175.00
2g USD 320.00
5g USD 550.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Corvaton; Morsydomine; N-(Ethoxycarbonyl)-3-(4-morpholinyl)sydnone imine; SIN-10; SIN10; SIN 10; Molsidomine
IUPAC/Chemical Name
(ethoxycarbonyl)(3-morpholino-1,2,3-oxadiazol-3-ium-5-yl)amide
InChi Key
XLFWDASMENKTKL-UHFFFAOYSA-N
InChi Code
InChI=1S/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3
SMILES Code
O=C([N-]C1=C[N+](N2CCOCC2)=NO1)OCC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
Molsidomine is a NO donor and annexin A2 inhibitor.
In vitro activity:
These findings prompted us to study the effects of SIN-10 and SIN-1 on the respiratory burst in human neutrophils. SIN-10 was more effective than SIN-1 in inhibiting superoxide anion (O2-) formation induced by N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMet-Leu-Phe) and by C5a. The effects of SIN-1 and SIN-10 on O2- formation were additive or less than additive, indicating the sydnonimines acted through a common mechanism. SIN-10 reduced fMet-Leu-Phe-induced rises in cytosolic Ca2+ concentration in neutrophils. Reference: Biochem Pharmacol. 1992 Aug 18;44(4):637-44. https://pubmed.ncbi.nlm.nih.gov/1324680/
In vivo activity:
This study evaluated the protective effect of molsidomine in diabetic neuropathy in rats. Treatment with molsidomine significantly improved motor coordination, paw withdrawal threshold, mechanical threshold, and nerve conduction velocity. Furthermore, molsidomine treatment also reduced malondialdehyde levels and prevented depletion of reduced glutathione in the sciatic nerve homogenate. Reference: Animal Model Exp Med. 2021 Mar 23;4(3):243-248. https://pubmed.ncbi.nlm.nih.gov/34557650/
Solvent mg/mL mM
Solubility
DMSO 74.5 307.55
Ethanol 24.0 99.08
Water 24.5 101.14
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 242.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Ervens J, Seifert R. Molsidomine inhibits the chemoattractant-induced respiratory burst in human neutrophils via a no-independent mechanism. Biochem Pharmacol. 1992 Aug 18;44(4):637-44. doi: 10.1016/0006-2952(92)90397-2. PMID: 1324680. 2. Nayak B P, Minaz N, Pasha K. Molsidomine ameliorates diabetic peripheral neuropathy complications in Wistar rats. Animal Model Exp Med. 2021 Mar 23;4(3):243-248. doi: 10.1002/ame2.12162. PMID: 34557650; PMCID: PMC8446713. 3. Roth L, Van der Donckt C, Emini Veseli B, Van Dam D, De Deyn PP, Martinet W, Herman AG, De Meyer GRY. Nitric oxide donor molsidomine favors features of atherosclerotic plaque stability and reduces myocardial infarction in mice. Vascul Pharmacol. 2019 Jul-Aug;118-119:106561. doi: 10.1016/j.vph.2019.05.001. Epub 2019 May 11. PMID: 31085310.
In vitro protocol:
1. Ervens J, Seifert R. Molsidomine inhibits the chemoattractant-induced respiratory burst in human neutrophils via a no-independent mechanism. Biochem Pharmacol. 1992 Aug 18;44(4):637-44. doi: 10.1016/0006-2952(92)90397-2. PMID: 1324680.
In vivo protocol:
1. Nayak B P, Minaz N, Pasha K. Molsidomine ameliorates diabetic peripheral neuropathy complications in Wistar rats. Animal Model Exp Med. 2021 Mar 23;4(3):243-248. doi: 10.1002/ame2.12162. PMID: 34557650; PMCID: PMC8446713. 2. Roth L, Van der Donckt C, Emini Veseli B, Van Dam D, De Deyn PP, Martinet W, Herman AG, De Meyer GRY. Nitric oxide donor molsidomine favors features of atherosclerotic plaque stability and reduces myocardial infarction in mice. Vascul Pharmacol. 2019 Jul-Aug;118-119:106561. doi: 10.1016/j.vph.2019.05.001. Epub 2019 May 11. PMID: 31085310.
1: Zordan P, Sciorati C, Campana L, Cottone L, Clementi E, Querini PR, Brunelli S. The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy. Eur J Pharmacol. 2013 Sep 5;715(1-3):296-303. doi: 10.1016/j.ejphar.2013.05.007. Epub 2013 May 23. PubMed PMID: 23707352. 2: Parfenyuk EV, Dolinina ES. Design of silica carrier for controlled release of molsidomine: effect of preparation methods of silica matrixes and their composites with molsidomine on the drug release kinetics in vitro. Eur J Pharm Biopharm. 2014 Nov;88(3):1038-45. doi: 10.1016/j.ejpb.2014.09.007. Epub 2014 Sep 28. PubMed PMID: 25269886. 3: Tirone M, Conti V, Manenti F, Nicolosi PA, D'Orlando C, Azzoni E, Brunelli S. Nitric Oxide Donor Molsidomine Positively Modulates Myogenic Differentiation of Embryonic Endothelial Progenitors. PLoS One. 2016 Oct 19;11(10):e0164893. doi: 10.1371/journal.pone.0164893. eCollection 2016. PubMed PMID: 27760216; PubMed Central PMCID: PMC5070765. 4: Idrisova EM, Kladieva EA, Borovkova NV, Vorob'eva EV, Chernov VI, Karpov RS. [Long-acting isosorbide dinitrate and molsidomin in the treatment of effort angina in patients with arterial hypotension]. Ter Arkh. 2002;74(6):63-6. Russian. PubMed PMID: 12136489. 5: Żorniak M, Mitręga KA, Porc M, Krzemiński TF. New approach to molsidomine active metabolites coming from the results of 2 models of experimental cardiology. Can J Physiol Pharmacol. 2017 Feb;95(2):111-121. doi: 10.1139/cjpp-2016-0251. Epub 2016 Oct 4. PubMed PMID: 27918857. 6: Wildgrube HJ, Ostrowski J, Chamberlain J, Gärtner W, Stockhausen H. Liver function and pharmacokinetics of molsidomine and its metabolite 3-morpholinosydnonimine in healthy volunteers. Arzneimittelforschung. 1986 Jul;36(7):1129-33. PubMed PMID: 3768083. 7: Messin R, Karpov Y, Baikova N, Bruhwyler J, Monseu MJ, Guns C, Géczy J. Short- and long-term effects of molsidomine retard and molsidomine nonretard on exercise capacity and clinical status in patients with stable angina: a multicenter randomized double-blind crossover placebo-controlled trial. J Cardiovasc Pharmacol. 1998 Feb;31(2):271-6. PubMed PMID: 9475269. 8: The ESPRIM trial: short-term treatment of acute myocardial infarction with molsidomine. European Study of Prevention of Infarct with Molsidomine (ESPRIM) Group. Lancet. 1994 Jul 9;344(8915):91-7. PubMed PMID: 7912393. 9: Fach WA, Kostanecka T, Kober G. [Long-term antihypertensive effect of delayed-action molsidomine]. Z Kardiol. 1994 Sep;83(9):646-51. German. PubMed PMID: 7801667. 10: Weidemann H, Schober B, Schuon J. Comparative study of long-term effects of Molsidomin 8 mg (slow release form) and ISDN 40 mg (slow release form) on angina pectoris and ischaemic ST-segment depression during maximal bicycle-ergometry in patients with coronary insufficiency. Eur Heart J. 1987 Oct;8 Suppl G:63-9. PubMed PMID: 3443128. 11: Monnin JL, Vinel JP, Le Quellec A, Pascal JP, Taourel P, Bruel JM, Blanc F, Michel H, Ciurana AJ. [Evaluation of the effects of molsidomine and propranolol-molsidomine combination on portal hemodynamics by pulsed Doppler ultrasound]. Gastroenterol Clin Biol. 1992;16(10):745-50. French. PubMed PMID: 1478400. 12: Kang M, Hashimoto A, Gade A, Akbarali HI. Interaction between hydrogen sulfide-induced sulfhydration and tyrosine nitration in the KATP channel complex. Am J Physiol Gastrointest Liver Physiol. 2015 Mar 15;308(6):G532-9. doi: 10.1152/ajpgi.00281.2014. Epub 2014 Dec 31. PubMed PMID: 25552582; PubMed Central PMCID: PMC4360042. 13: Wöhrle J, Höher M, Nusser T, Hombach V, Kochs M. No effect of highly dosed nitric oxide donor molsidomine on the angiographic restenosis rate after percutaneous coronary angioplasty: a randomized, placebo controlled, double-blind trial. Can J Cardiol. 2003 Apr;19(5):495-500. PubMed PMID: 12717484. 14: Kmieć M, Ochmański W. [Molsidomine: importance in treatment of circulation disorders]. Przegl Lek. 1998;55(10):532-6. Review. Polish. PubMed PMID: 10224868. 15: Uribe P, Boguen R, Treulen F, Sánchez R, Villegas JV. Peroxynitrite-mediated nitrosative stress decreases motility and mitochondrial membrane potential in human spermatozoa. Mol Hum Reprod. 2015 Mar;21(3):237-43. doi: 10.1093/molehr/gau107. Epub 2014 Nov 25. PubMed PMID: 25425609. 16: Darius H, Erbel R, Rupprecht HJ, Pop T, Meyer J. [Acute and chronic effects of molsidomine in therapeutic coronary angioplasty]. Med Klin (Munich). 1990 Feb;85 Suppl 1:23-6. German. PubMed PMID: 2185404. 17: Spreux-Varoquaux O, Doll J, Dutot C, Grandjean N, Cordonnier P, Pays M, Andrieu J, Advenier C. Pharmacokinetics of molsidomine and its active metabolite, linsidomine, in patients with liver cirrhosis. Br J Clin Pharmacol. 1991 Sep;32(3):399-401. PubMed PMID: 1777378; PubMed Central PMCID: PMC1368538. 18: Drummer C, Valta-Seufzer U, Karrenbrock B, Heim JM, Gerzer R. Comparison of anti-platelet properties of molsidomine, isosorbide-5-mononitrate and placebo in healthy volunteers. Eur Heart J. 1991 Apr;12(4):541-9. PubMed PMID: 1648488. 19: Rosenkranz B, Winkelmann BR, Parnham MJ. Clinical pharmacokinetics of molsidomine. Clin Pharmacokinet. 1996 May;30(5):372-84. PubMed PMID: 8743336. 20: Messin R, Bruhwyler J, Dubois C, Famaey JP, Géczy J. Tolerability to 1-year treatment with once-daily molsidomine in patients with stable angina. Adv Ther. 2006 Jul-Aug;23(4):601-14. PubMed PMID: 17050502.